Creation and Validation of a Photonumeric Scale for Assessment of Infraorbital Hollows.

Background: Validated clinical scales are needed to assess aesthetic improvement of the infraorbital hollows (IOHs) after treatment with dermal fillers.

Objective: To develop an IOHs scale and establish its reliability and sensitivity for grading subjects in clinical trials or routine practice.

Methods And Materials: The Teoxane IOHs Scale (TIOHS), a 5-grade photonumeric scale, was developed based on real-subject photographs and validated through photographic and live subjects' evaluation.

Creation and validation of a photonumeric scale for assessment of lip fullness.

Background: Validated, objective clinical scales are needed to assess aesthetic improvement of the lips after augmentation with dermal fillers.

Objective: To develop a lip fullness rating scale and establish its reliability for grading subjects in clinical trials or routine practice, and sensitivity for detecting clinically meaningful changes.

Methods: The Teoxane Lip Fullness Scale (TLFS), a proprietary, 5-grade photonumeric scale, was developed by clinical experts based on real subject photographs and was validated through both photographic and live subjects' evaluation.

Efficacy and Safety of a New Resilient Hyaluronic Acid Filler in the Correction of Moderate-to-Severe Dynamic Perioral Rhytides: A 52-Week Prospective, Multicenter, Controlled, Randomized, Evaluator-Blinded Study.

Background: The perioral region is highly mobile and subject to multifactorial changes during aging. Resilient Hyaluronic Acid Redensity (RHAR), an RHA filler, was developed with the aim of optimizing outcomes in dynamic facial areas.

Objective: This randomized, blinded, multicenter clinical study aimed to demonstrate superiority of RHAR over no-treatment control for correction of moderate-to-severe dynamic perioral rhytides.

Retraction of the Plunger on a Syringe of Hyaluronic Acid Before Injection: Are We Safe?

Background: Controversy exists concerning the need for aspiration before injection with hyaluronic acid (HA) fillers.

Objective: The authors undertook a study of HA products to determine if blood could be aspirated back into a syringe of HA when the needle has been primed or filled with HA.

Methods And Materials: Two studies were set up to determine if or when blood could be withdrawn from a heparinized fresh tube of blood into the HA syringe.

Incorrect reconstitution of incobotulinumtoxinA leads to loss of neurotoxin.

Background: IncobotulinumtoxinA (INCO) was approved for aesthetic use in the United States in 2011. When reconstituted per manufacturer's instructions, diminished delivery of INCO in US may result.

Objective: Investigators sought to determine whether potential loss of decreased motor activity could be demonstrated, using a simple reconstitution technique.

Quality of life in plaque psoriasis patients treated with voclosporin: a Canadian phase III, randomized, multicenter, double-blind, placebo-controlled study.

Background: Quality of life assessments are important in the evaluation of new therapies for psoriasis.

Objective: To determine the effect of voclosporin (VCS) treatment on quality of life in patients with psoriasis.

Patients And Methods: 451 plaque psoriasis patients with ≥  10% body surface area involvement were randomly assigned in a double-blind fashion to 1 of 4 treatment groups (placebo, VCS 0.

Psoriasis care: new and emerging pharmacologic trends.

Background: The first Canadian Guidelines for the Management of Plaque Psoriasis were recently published, reflecting an evidence-based analysis of psoriasis therapies available in Canada. The guidelines advocate patient-centered psoriasis care in which physicians explore appropriate options to find safe therapies that patients will adhere to and be satisfied with over the long term.

Objective: To update the discussion in the guidelines regarding new and emerging therapies and trends in psoriasis clinical research.

A favourable benefit/risk ratio with efalizumab: a review of the clinical evidence.

Moderate to severe plaque psoriasis has traditionally been treated with agents that have toxicities associated with long-term use. Many patients therefore cannot be treated safely, conveniently or effectively with traditional therapies. Recent phase 3 clinical trials for efalizumab, a biological agent targeted specifically at the T-cell-based pathology of psoriasis, have demonstrated its short- and long-term efficacy and safety for the treatment of psoriasis.

Relapse, rebound, and psoriasis adverse events: an advisory group report.

Psoriasis is a chronic disease, the severity of which varies among patients and changes unpredictably over time in individual patients. Psoriasis can be exacerbated during treatment by infection, endocrine factors, hypocalcemia, medications, psychologic stress, skin trauma, or other factors. Patients who discontinue treatments may experience a return of disease--relapse--or worsening of disease--rebound.

Randomized, double-blind comparison of the efficacy of two hyaluronic acid derivatives, restylane perlane and hylaform, in the treatment of nasolabial folds.

Background: Cross-linked hyaluronic acid gels may offer longer-lasting cosmetic correction and a lower risk of immunogenicity than other soft tissue augmentation agents.

Objective: To compare the efficacy and safety of a non-animal-stabilized hyaluronic acid gel (Restylane Perlane, Q-Med, Uppsala, Sweden) with that of a hylan B gel (Hylaform, Genzyme Corp., Cambridge, MA, USA), a cross-linked hyaluronic acid from chicken combs, for treatment of nasolabial folds.

Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience.

Background: Because many therapies for psoriasis disrupt the normal inflammatory cascade and could theoretically impair the body's ability to respond to external pathogens, a possible increase in the incidence of infection is a concern with any new psoriasis therapy that affects the immune system. Efalizumab is a biologic therapy targeted to inhibit T cells. Its efficacy has been shown in clinical trials encompassing >3500 patients with psoriasis.

Dermatologic surgery practice and skin cancer treatment in Canada: results of a national survey.

Background: Although traditionally considered a medical subspecialty, dermatology has rapidly evolved over the past two decades to encompass a wide variety of cutaneous surgical procedures.

Objective: The study was carried out to evaluate the status of dermatologic surgery practice and skin cancer treatment in Canada.

Methods: In 2003, 550 practicing Canadian dermatologists were surveyed.

Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.

Objective: To assess the efficacy and safety of a 24-week course of efalizumab.

Design: Phase 3, randomized, double-blind, parallel-group, placebo-controlled 12-week study followed by a 12-week open-label study.

Setting: Outpatient dermatology clinics.

Multiple nevoid malignant melanomas in a patient with AIDS: the role of proliferating cell nuclear antigen in the diagnosis.

The rapid growth of lesions clinically resembling compound nevi in patients with HIV/AIDS should alert physicians to the possibility of malignant melanomas. Immunohistochemistry for proliferating cell nuclear antigen can be helpful in the diagnosis of these tumors. A case of multiple primary nevoid melanomas in a patient with HIV/AIDS is reported.